Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

No effect of dietary fat on short-term weight gain in mice treated with atypical antipsychotic drugs

International Journal of Obesity volume 31, pages 1014–1022 (2007)Cite this article

Abstract

Rationale:

Atypical antipsychotic drugs (AAD) induce significant weight gain in female C57BL/6J mice. The effect of dietary fat on weight gain and serum lipids in this model is unknown.

Objectives:

Test the hypothesis that the obesigenic effects of these drugs are greater in the presence of a high-fat diet.

Methods:

Female C57BL/6J mice were treated with atypical antipsychotics for 3 weeks and fed either a low-fat or high-fat diet (4.6 vs 15.6% fat by wt). Food intake (FI), body weight (BW), body composition, and serum lipids were measured during treatment with optimized doses of olanzapine, quetiapine, and risperidone. Energy intake (EI) and feed efficiency (FE) were calculated. Group differences in change were analyzed via repeated measures analysis of variance (ANOVA). Serum lipid concentrations, EI and FE were compared using two-way ANOVA.

Results:

AAD-treated mice gained significantly more weight than controls after 3 weeks (P<0.001). Treatment and diet had significant effects on FI and EI over time (P<0.001). AAD-treated mice had significantly higher FE than controls (P<0.05); however, there was no significant drug by diet interaction (P=0.65). Risperidone low-fat mice gained significantly more absolute fat mass than placebo low-fat mice (P<0.05). All treatment groups, except quetiapine low-fat and olanzapine high-fat, gained significantly more absolute lean mass than placebo controls (P<0.05). Cholesterol levels were significantly lower in quetiapine and risperidone than placebo (P<0.05). Risperidone low-fat mice had significantly higher triglyceride levels than placebo and risperidone high-fat mice (P<0.05).

Conclusions:

A high-fat diet does not increase AAD-induced BW gain in female mice during a 3-week treatment period.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004; 110: 2952–2967.

    Article  PubMed  Google Scholar 

  2. Baskin ML, Ard J, Franklin F, Allison DB . Prevalence of obesity in the United States. Obes Rev 2005; 6: 5–7.

    Article  CAS  PubMed  Google Scholar 

  3. Homel P, Casey D, Allison DB . Changes in body mass index for individuals with and without schizophrenia, 1987–1996. Schizophr Res 2002; 55: 277–284.

    Article  PubMed  Google Scholar 

  4. Nasrallah H . A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003; 28: 83–96.

    Article  CAS  PubMed  Google Scholar 

  5. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999; 60: 215–220.

    Article  CAS  PubMed  Google Scholar 

  6. Fontaine KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, Casey DE et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 2001; 101: 277–288.

    Article  CAS  PubMed  Google Scholar 

  7. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–1696.

    CAS  PubMed  Google Scholar 

  8. McIntyre RS, Trakas K, Lin D, Balshaw R, Hwang P, Robinson K et al. Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Can J Psychiatry 2003; 48: 689–694.

    Article  PubMed  Google Scholar 

  9. McIntyre RS, McCann SM, Kennedy SH . Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001; 46: 273–281.

    Article  CAS  PubMed  Google Scholar 

  10. Casey DE . Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65: 27–35.

    CAS  PubMed  Google Scholar 

  11. Meyer JM, Koro CE . The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70: 1–17.

    Article  PubMed  Google Scholar 

  12. Gupta S, Steinmeyer C, Frank B, Madhusoodanan S, Lockwood K, Lentz B et al. Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy. Am J Ther 2003; 10: 348–355.

    Article  PubMed  Google Scholar 

  13. Wirshing DA . Adverse effects of atypical antipsychotics. J Clin Psychiatry 2001; 62: 7–10.

    CAS  PubMed  Google Scholar 

  14. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005; 62: 19–28.

    Article  CAS  PubMed  Google Scholar 

  15. Aquila R, Emanuel M . Interventions for weight gain in adults treated with novel antipsychotics. Prim Care Companion J Clin Psychiatry 2000; 2: 20–23.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Allison DB, Casey DE . Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62: 22–31.

    CAS  PubMed  Google Scholar 

  17. Kurzthaler I, Fleischhacker WW . The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 2001; 62: 32–37.

    CAS  PubMed  Google Scholar 

  18. Weiden PJ, Mackell JA, McDonnell DD . Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004; 66: 51–57.

    Article  PubMed  Google Scholar 

  19. Osby U, Correia N, Brandt L, Ekbom A, Sparen P . Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000; 45: 21–28.

    Article  CAS  PubMed  Google Scholar 

  20. Newcomer JW . Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19: 1–93.

    Article  CAS  PubMed  Google Scholar 

  21. Bobes J, Rejas J, Garcia-Garcia M, Rico-Villademoros F, Garcia-Portilla MP, Fernandez I et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res 2003; 62: 77–88.

    Article  CAS  PubMed  Google Scholar 

  22. Meyer JM, Koro CE . The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70: 1–17.

    Article  PubMed  Google Scholar 

  23. Atmaca M, Kuloglu M, Tezcan E, Ustundag B . Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003; 64: 598–604.

    Article  CAS  PubMed  Google Scholar 

  24. Meyer JM . Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001; 21: 369–374.

    Article  CAS  PubMed  Google Scholar 

  25. Melkersson KI, Hulting AL, Brismar KE . Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000; 61: 742–749.

    Article  CAS  PubMed  Google Scholar 

  26. Bouchard RH, Demers MF, Simoneau I, Almeras N, Villeneuve J, Mottard JP et al. Atypical antipsychotics and cardiovascular risk in schizophrenic patients. J Clin Psychopharmacol 2001; 21: 110–111.

    Article  CAS  PubMed  Google Scholar 

  27. Martin A, L'Ecuyer S . Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study. Eur Child Adolesc Psychiatry 2002; 11: 129–133.

    Article  CAS  PubMed  Google Scholar 

  28. Goodnick PJ, Jerry JM . Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother 2002; 3: 1773–1781.

    Article  CAS  PubMed  Google Scholar 

  29. Kingsbury SJ, Fayek M, Trufasiu D, Zada J, Simpson GM . The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 2001; 62: 347–349.

    Article  CAS  PubMed  Google Scholar 

  30. West DB, Boozer CN, Moody DL, Atkinson RL . Dietary obesity in nine inbred mouse strains. Am J Physiol 1992; 262: R1025–R1032.

    CAS  PubMed  Google Scholar 

  31. Petro AE, Cotter J, Cooper DA, Peters JC, Surwit SJ, Surwit RS . Fat, carbohydrate, and calories in the development of diabetes and obesity in the C57BL/6J mouse. Metabolism 2004; 53: 454–457.

    Article  CAS  PubMed  Google Scholar 

  32. Winzell MS, Ahren B . The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 2004; 53: S215–S219.

    Article  PubMed  Google Scholar 

  33. Cope MB, Nagy TR, Fernandez JR, Geary N, Casey DE, Allison DB . Antipsychotic drug-induced weight gain: development of an animal model. Int J Obes Relat Metab Disord 2005; 29: 607–614.

    Article  CAS  Google Scholar 

  34. Nagy TR, Clair AL . Precision and accuracy of dual-energy X-ray absorptiometry for determining in vivo body composition of mice. Obes Res 2000; 8: 392–398.

    Article  CAS  PubMed  Google Scholar 

  35. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 2002; 159: 1055–1057.

    Article  PubMed  Google Scholar 

  36. Stanton JM . Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995; 21: 463–472.

    Article  CAS  PubMed  Google Scholar 

  37. Kalinichev M, Rourke C, Daniels AJ, Grizzle MK, Britt CS, Ignar DM et al. Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology (Berl) 2005; 182: 220–231.

    Article  CAS  Google Scholar 

  38. Baptista T, de Baptista EA, Lalonde J, Plamondon J, Kin NM, Beaulieu S et al. Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 1305–1311.

    Article  CAS  PubMed  Google Scholar 

  39. Baptista T . Mechanisms of weight gain induced by antipsychotic drugs. J Clin Psychiatry 2002; 63: 245–246.

    Article  PubMed  Google Scholar 

  40. Baptista T, Zarate J, Joober R, Colasante C, Beaulieu S, Paez X et al. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 2004; 5: 279–299.

    Article  CAS  PubMed  Google Scholar 

  41. Ravussin E . Low resting metabolic rate as a risk factor for weight gain: role of the sympathetic nervous system. Int J Obes Relat Metab Disord 1995; 19: S8–S9.

    PubMed  Google Scholar 

  42. Buscemi S, Verga S, Caimi G, Cerasola G . Low relative resting metabolic rate and body weight gain in adult Caucasian Italians. Int J Obes (Lond) 2005; 29: 287–291.

    Article  CAS  Google Scholar 

  43. Trayhurn P . Thermoregulation in the diabetic-obese (db/db) mouse. The role of non-shivering thermogenesis in energy balance. Pflugers Arch 1979; 380: 227–232.

    Article  CAS  PubMed  Google Scholar 

  44. Trayhurn P, James WP . Thermoregulation and non-shivering thermogenesis in the genetically obese (ob/ob) mouse. Pflugers Arch 1978; 373: 189–193.

    Article  CAS  PubMed  Google Scholar 

  45. Blass DM, Chuen M . Olanzapine-associated hypothermia. Psychosomatics 2004; 45: 135–139.

    Article  PubMed  Google Scholar 

  46. Brevik A, Farver D . Atypical antipsychotic induced mild hypothermia. S D J Med 2003; 56: 67–70.

    PubMed  Google Scholar 

  47. Hagg S, Mjorndal T, Lindqvist L . Repeated episodes of hypothermia in a subject treated with haloperidol, levomepromazine, olanzapine, and thioridazine. J Clin Psychopharmacol 2001; 21: 113–115.

    Article  CAS  PubMed  Google Scholar 

  48. Parris C, Mack JM, Cochiolo JA, Steinmann AF, Tietjen J . Hypothermia in 2 patients treated with atypical antipsychotic medication. J Clin Psychiatry 2001; 62: 61–63.

    Article  CAS  PubMed  Google Scholar 

  49. Phan TG, Yu RY, Hersch MI . Hypothermia induced by risperidone and olanzapine in a patient with Prader–Willi syndrome. Med J Aust 1998; 169: 230–231.

    CAS  PubMed  Google Scholar 

  50. Razaq M, Samma M . A case of risperidone-induced hypothermia. Am J Ther 2004; 11: 229–230.

    Article  PubMed  Google Scholar 

  51. Sharpe JK, Hills AP, Byrne NM, Stedman TJ . Resting metabolic rate in people taking atypical antipsychotic medication. Asia Pac J Clin Nutr 2004; 13: S157.

    Google Scholar 

  52. Arjona AA, Zhang SX, Adamson B, Wurtman RJ . An animal model of antipsychotic-induced weight gain. Behav Brain Res 2004; 152: 121–127.

    CAS  PubMed  Google Scholar 

  53. Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, Hummer M et al. Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 2001; 158: 1719–1722.

    Article  CAS  PubMed  Google Scholar 

  54. Graham KA, Perkins DO, Edwards LJ, Barrier Jr RC, Lieberman JA, Harp JB . Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005; 162: 118–123.

    Article  PubMed  Google Scholar 

  55. Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH . The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004; 74: 1999–2008.

    Article  CAS  PubMed  Google Scholar 

  56. Fell MJ, Marshall KM, Williams J, Neill JC . Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J Psychopharmacol 2004; 18: 149–155.

    Article  CAS  PubMed  Google Scholar 

  57. Minet-Ringuet J, Even PC, Guesdon B, Tome D, de Beaurepaire R . Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection. Behav Brain Res 2005; 163: 204–211.

    Article  CAS  PubMed  Google Scholar 

  58. Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005; 54: 862–871.

    Article  CAS  PubMed  Google Scholar 

  59. Lewis DS, Bertrand HA, Masoro EJ, McGill Jr HC, Carey KD, McMahan CA . Preweaning nutrition and fat development in baboons. J Nutr 1983; 113: 2253–2259.

    Article  CAS  PubMed  Google Scholar 

  60. Spencer SA, Vinter J, Hull D . The effect in newborn rabbits of overfeeding on fat deposition, gross energetic efficiency, and metabolic rate. Pediatr Res 1985; 19: 127–130.

    Article  CAS  PubMed  Google Scholar 

  61. McCracken KJ, McNiven MA . Effects of overfeeding by gastric intubation on body composition of adult female rats and on heat production during feeding and fasting. Br J Nutr 1983; 49: 193–202.

    Article  CAS  PubMed  Google Scholar 

  62. Applegate EA, Upton DE, Stern JS . Exercise and detraining: effect on food intake, adiposity and lipogenesis in Osborne–Mendel rats made obese by a high fat diet. J Nutr 1984; 114: 447–459.

    Article  CAS  PubMed  Google Scholar 

  63. Coccurello R, Caprioli A, Ghirardi O, Conti R, Ciani B, Daniele S et al. Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects. Psychopharmacology (Berl) 2006; 186: 561–571.

    Article  CAS  Google Scholar 

  64. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–1223.

    Article  CAS  PubMed  Google Scholar 

  65. Almeras N, Despres JP, Villeneuve J, Demers MF, Roy MA, Cadrin C et al. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry 2004; 65: 557–564.

    Article  CAS  PubMed  Google Scholar 

  66. Moghadasian MH, Frohlich JJ, McManus BM . Advances in experimental dyslipidemia and atherosclerosis. Lab Invest 2001; 81: 1173–1183.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported in part by NIH Grants DK068261, F32DK064532, and P30DK56336. Eli Lilly & Co. and AstraZeneca donated olanzapine and quetiapine, respectively.

Author information

Authors and Affiliations

  1. Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, USA

    M B Cope, P Jumbo-Lucioni, R G Walton, R A Kesterson, D B Allison & T R Nagy

  2. Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA

    R A Kesterson

  3. Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA

    D B Allison

Authors
  1. M B Cope
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Jumbo-Lucioni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R G Walton
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R A Kesterson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D B Allison
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T R Nagy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T R Nagy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cope, M., Jumbo-Lucioni, P., Walton, R. et al. No effect of dietary fat on short-term weight gain in mice treated with atypical antipsychotic drugs. Int J Obes 31, 1014–1022 (2007). https://doi.org/10.1038/sj.ijo.0803533

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0803533

Keywords

This article is cited by

Search

Advanced search

Quick links